Arrowhead Pharmaceuticals Inc. (ARWR) recently reported financial results for its fiscal first quarter ended December 31, 2019.
On 21 Feb 2020, Arrowhead Pharmaceuticals, Inc. stock recognized change of 122.87% far from 52-week low rate and just recently located move of -47.79% off 52-week high cost. ARWR stock has been tape-recorded -28.91% far from 50 day moving average and 0.85% far from 200 day moving average. Moving better, we can see that shares have actually been trading -9.38% off 20-day moving average.
Picked Recent Events
Began dosing clients and completed registration of the first consecutive friend in the AROAAT2002 research study, a pilot open-label, multi-dose, Phase 2 research study to evaluate modifications in a novel histological activity scale in response to ARO-AAT with time in clients with alpha-1 antitrypsin shortage associated liver illness
Specified interim multiple-dose results on 2 cardiometabolic prospects ARO-APOC3, being developed as a prospective treatment for clients with serious hypertriglyceridemia, and ARO-ANG3, being established for the treatment of dyslipidemias and metabolic diseases, showing high levels of reduction in APOC3, ANGPTL3, triglycerides, and other lipid specifications
Presented single-dose medical data on ARO-APOC3 and ARO-ANG3 in two late-breaking oral discussions at the American Heart Association Scientific Sessions 2019
Expanded Arrowheads senior management group with the hiring of skilled biotech and pharma leaders Dr. Javier San Martin as chief medical officer, Dr. Curt Bradshaw as primary clinical officer, and Jim Hassard as chief commercial officer
Designated Dr. Marianne De Backer as a brand-new independent director; Marianne is currently Executive Vice President, Head of Global Business Development & & Licensing, and a member of the Executive Committee of the Pharmaceuticals Division of Bayer AG
Presented preclinical data at the North American Cystic Fibrosis Conference on ARO-ENaC, Arrowheads first TRiMTM-enabled inhaled, lung prospect for the treatment of cystic fibrosis, which is on schedule for a CTA filing in the very first half of 2020
Hosted an expert R&D day to talk about Arrowheads item development technique, scientific prospects, and some amazing advancements being made to the TRiMTM platform, which can now reach numerous cell types and be used in a dimer structure that provides several siRNA series together to accomplish high levels of knockdown of two different genes all at once
The typical volatility for the week at 4.35% and for month was at 5.45%. There are 104.95 M shares outstanding and 98.88 M shares are floated in market.
Enhanced the balance sheet and extended Arrowheads cash runway with a financing with gross proceeds of about $267M.
Completed regulatory submissions to begin Phase 1 studies of ARO-HSD for the treatment of alcohol and nonalcohol associated liver disease, and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. Both programs are on schedule to possibly start dosing patients this quarter or early in the second quarter
On 21 Feb 2020, Arrowhead Pharmaceuticals, Inc. stock determined modification of 122.87% away from 52-week low price and recently situated move of -47.79% off 52-week high rate. ARWR stock has been recorded -28.91% away from 50 day moving average and 0.85% away from 200 day moving average. The typical volatility for the week at 4.35% and for month was at 5.45%.